Retirement Systems of Alabama Sells 544 Shares of DaVita Inc. $DVA

Retirement Systems of Alabama trimmed its position in shares of DaVita Inc. (NYSE:DVA) by 5.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 8,911 shares of the company’s stock after selling 544 shares during the quarter. Retirement Systems of Alabama’s holdings in DaVita were worth $1,269,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the company. Invesco Ltd. boosted its holdings in DaVita by 3.4% during the 1st quarter. Invesco Ltd. now owns 1,642,947 shares of the company’s stock worth $251,322,000 after acquiring an additional 53,402 shares during the last quarter. Northern Trust Corp boosted its holdings in DaVita by 20.2% during the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock worth $136,240,000 after acquiring an additional 149,858 shares during the last quarter. Gates Capital Management Inc. boosted its holdings in DaVita by 0.7% during the 1st quarter. Gates Capital Management Inc. now owns 722,205 shares of the company’s stock worth $110,476,000 after acquiring an additional 4,698 shares during the last quarter. Amundi boosted its holdings in DaVita by 16.0% during the 1st quarter. Amundi now owns 517,690 shares of the company’s stock worth $79,584,000 after acquiring an additional 71,304 shares during the last quarter. Finally, Epoch Investment Partners Inc. boosted its holdings in DaVita by 10.7% during the 1st quarter. Epoch Investment Partners Inc. now owns 407,921 shares of the company’s stock worth $62,400,000 after acquiring an additional 39,485 shares during the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on DVA shares. Zacks Research downgraded shares of DaVita from a “hold” rating to a “strong sell” rating in a report on Thursday, October 30th. Cowen reissued a “hold” rating on shares of DaVita in a report on Monday. Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a report on Wednesday, October 8th. Wall Street Zen downgraded shares of DaVita from a “buy” rating to a “hold” rating in a report on Saturday, October 11th. Finally, TD Cowen cut their price target on shares of DaVita from $154.00 to $133.00 and set a “hold” rating on the stock in a report on Monday. Five analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, DaVita has an average rating of “Reduce” and a consensus target price of $148.00.

DaVita Stock Up 1.0%

NYSE DVA opened at $121.21 on Thursday. The company has a market cap of $8.56 billion, a PE ratio of 12.48, a price-to-earnings-growth ratio of 0.91 and a beta of 1.13. DaVita Inc. has a 52 week low of $115.39 and a 52 week high of $179.60. The firm’s 50-day simple moving average is $129.72 and its two-hundred day simple moving average is $136.16.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $3.17 by ($0.66). DaVita had a net margin of 5.80% and a return on equity of 815.62%. The company had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.43 billion. During the same quarter in the prior year, the company earned $2.59 earnings per share. The company’s quarterly revenue was up 4.8% on a year-over-year basis. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. As a group, equities research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.